90 related articles for article (PubMed ID: 15032078)
21. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
Brustmann H
Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
[TBL] [Abstract][Full Text] [Related]
22. [Assessment of the AgNORs count in serous ovarian cancer].
Gottwald L; Danilewicz M; Suzin J; Bieńkiewicz A
Ginekol Pol; 2004 Oct; 75(10):770-5. PubMed ID: 15587908
[TBL] [Abstract][Full Text] [Related]
23. [Ovarian cancer metastasis to the greater omentum].
Vinokurov VL; Kolosov AE
Vopr Onkol; 1980; 26(2):30-4. PubMed ID: 7361492
[TBL] [Abstract][Full Text] [Related]
24. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
25. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal.
Singh N; Gilks CB; Wilkinson N; McCluggage WG
Histopathology; 2014 Aug; 65(2):149-54. PubMed ID: 24660659
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
27. Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome.
Hsu CY; Kurman RJ; Vang R; Wang TL; Baak J; Shih IeM
Hum Pathol; 2005 Oct; 36(10):1049-54. PubMed ID: 16226103
[TBL] [Abstract][Full Text] [Related]
28. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary.
Malpica A; Deavers MT
Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
30. [Expression of EVEC in ovarian carcinoma and its biological significance].
Wang Q; Li XG; Zhang Y; Cao LQ; Deng ZH; Chen Y
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):676-80. PubMed ID: 21122382
[TBL] [Abstract][Full Text] [Related]
31. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.
Mutch DG; Prat J
Gynecol Oncol; 2014 Jun; 133(3):401-4. PubMed ID: 24878391
[No Abstract] [Full Text] [Related]
32. [Clinicopathological characteristics of hereditary ovarian cancer syndrome].
Zhong Y; Sheng XG; Ma ZF; Ma YB; Liu NF; Chen YT; Gao R; Wang YY; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):676-80. PubMed ID: 20079180
[TBL] [Abstract][Full Text] [Related]
33. The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer.
Lee JY; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Ann Surg Oncol; 2014 Aug; 21(8):2762-6. PubMed ID: 24770785
[TBL] [Abstract][Full Text] [Related]
34. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
Goldstein NS; Uzieblo A
Am J Clin Pathol; 2002 Apr; 117(4):541-5. PubMed ID: 11939727
[TBL] [Abstract][Full Text] [Related]
35. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma.
Choi CH; Kim TJ; Kim WY; Ahn GH; Lee JW; Kim BG; Lee JH; Bae DS
Gynecol Oncol; 2007 Jun; 105(3):762-8. PubMed ID: 17383715
[TBL] [Abstract][Full Text] [Related]
36. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
Motohara T; Tashiro H; Miyahara Y; Sakaguchi I; Ohtake H; Katabuchi H
Cancer Sci; 2010 Jun; 101(6):1550-6. PubMed ID: 20384630
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
38. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
39. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
Takeshima N; Hirai Y; Umayahara K; Fujiwara K; Takizawa K; Hasumi K
Gynecol Oncol; 2005 Nov; 99(2):427-31. PubMed ID: 16112718
[TBL] [Abstract][Full Text] [Related]
40. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
